---
layout: archive
title: "Publications"
permalink: /publications/
author_profile: true
---

Full list of publications
------

Publications are listed in a chronological order from oldest to newest.

‚ú± - equal contribution
‚úâ - corresponding author
üÖ° ‚Äì review article
üÖù ‚Äì news & views article
üÖü ‚Äì pre-print 

1.	**Suskiewicz, M. J.**, Sussman, J. L.‚úâ, Silman, I. & Shaul, Y.‚úâ Context-dependent resistance to proteolysis of intrinsically disordered proteins. Protein Sci. 20, 1285‚Äì1297 (2011). üÖ°
2.	**Suskiewicz, M. J.** & Clausen, T.‚úâ Chemical biology interrogates protein arginine phosphorylation. Cell Chem. Biol. 23, 888‚Äì890 (2016). üÖù
3.	Trentini, D. B.‚ú±, **Suskiewicz, M. J.‚ú±**, Heuck, A., Kurzbauer, R., Deszcz, L., Mechtler, K. & Clausen, T. ‚úâ Arginine phosphorylation marks proteins for degradation by a Clp protease. Nature 539, 48‚Äì53 (2016).
4.	Heuck, A.‚ú±, Schitter-Sollner, S.‚ú±, **Suskiewicz, M. J.‚ú±**, Kurzbauer, R., Kley, J., Schleiffer, A., Rombaut, P., Herzog, F. & Clausen, T. ‚úâ Structural basis for the disaggregase activity and regulation of Hsp104. Elife 5, e21516 (2016).
5.	**Suskiewicz, M. J.**, Hajdusits, B., Beveridge, R., Heuck, A., Vu, L. D., Kurzbauer, R., Hauer, K., Thoeny, V., Rumpel, K., Mechtler, K., Meinhart, A., Clausen, T.‚úâ Structure of McsB, a protein kinase for regulated arginine phosphorylation. Nat. Chem. Biol. 15, 510‚Äì518 (2019).
6.	**Suskiewicz, M. J.**, Zobel, F., Ogden, T. E. H., Fontana, P., Ariza, A., Yang, J.-C., Zhu, K., Bracken, L., Hawthorne, W. J., Ahel, D., Neuhaus, D. & Ahel, I.‚úâ HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation. Nature 579, 598‚Äì602 (2020).
7.	Bilokapic, S., **Suskiewicz, M. J.**, Ahel, I. & Halic, M.‚úâ Bridging of DNA breaks activates PARP2‚ÄìHPF1 to modify chromatin. Nature 585, 609‚Äì613 (2020).
8.	**Suskiewicz, M. J.**, Palazzo, L., Hughes, R. & Ahel, I.‚úâ Progress and outlook in studying the substrate specificities of PARPs and related enzymes. FEBS J. 288, 2131‚Äì2142 (2021). üÖ°
9.	Asanoviƒá, I., Strandback, E., Kroupova, A., Pasajlic, D., Meinhart, A., Tsung-Pin, P., Djokovic, N., Anrather, D., Schuetz, T., **Suskiewicz, M. J.**, Sillamaa, S., K√∂cher, T., Beveridge, R., Nikolic, K., Schleiffer, A., Jinek, M., Hartl, M., Clausen, T., Penninger, J., Macheroux, P., Weitzer, S., Martinez, J.‚úâ The oxidoreductase PYROXD1 uses NAD (P)+ as an antioxidant to sustain tRNA ligase activity in pre-tRNA splicing and unfolded protein response. Mol. Cell 81, 2520‚Äì2532 (2021).
10.	Prokhorova, E.‚ú±, Agnew, T.‚ú±, Wondisford, A. R., Tellier, M., Kaminski, N., Beijer, D., Holder, J., Groslambert, J., **Suskiewicz, M. J.**, Zhu, K., Reber, J. M., Krassnig, S. C., Palazzo, L., Murphy, S., Nielsen, M. L., Mangerich, A., Ahel, D., Baets, J., O‚ÄôSullivan, R. J. & Ahel, I.‚úâ Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease. Mol. Cell 81, 2640-2655.e8 (2021).
11.	Prokhorova, E.‚ú±, Zobel, F.*, Smith, R., Zentout, S., Gibbs-Seymour, I., Sch√ºtzenhofer, K., Peters, A., Groslambert, J., Zorzini, V., Agnew, T., Brognard, J., Nielsen, M. L., Ahel, D., Huet, S., **Suskiewicz, M. J.‚úâ** & Ahel, I.‚úâ Serine-linked PARP1 auto-modification controls PARP inhibitor response. Nat. Commun. 12, 4055 (2021).
12.	Hajdusits, B.‚ú±, **Suskiewicz, M. J.‚ú±**, Hundt, N.‚ú±, Meinhart, A., Kurzbauer, R., Leodolter, J., Kukura, P.‚úâ & Clausen, T.‚úâ McsB forms a gated kinase chamber to mark aberrant bacterial proteins for degradation. Elife 10, e63505 (2021).
13.	Palazzo, L., **Suskiewicz, M. J.** & Ahel, I.‚úâ Serine ADP-ribosylation in DNA-damage response regulation. Curr. Opin. Genet. Dev. 71, 106‚Äì113 (2021). üÖ°
14.	Bergoug, M., Mosrin, C., Godin, F., Doudeau, M., Sosic, I., **Suskiewicz, M.**, Vall√©e, B. & B√©n√©detti, H.‚úâ Noncanonical structural requirements of neurofibromin SUMOylation reveal a folding-deficiency of several pathogenic mutants. bioRxiv 2021‚Äì12 (2021).
15.	Zhu, K., **Suskiewicz, M. J.‚úâ**, Hlou≈°ek-Kasun, A., Meudal, H., Mikoƒç, A., Aucagne, V.‚úâ, Ahel, D.‚úâ & Ahel, I. DELTEX E3 ligases ubiquitylate ADP-ribosyl modification on protein substrates. Sci. Adv. 8, eadd4253 (2022).
16.	Hunia, J., Gawalski, K., Szredzka, A., **Suskiewicz, M. J.** & Nowis, D.‚úâ The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. Front. Mol. Biosci. 9, 1073797 (2022). üÖ°
17.	Fontana, P., Buch-Larsen, S. C., Suyari, O., Smith, R., **Suskiewicz, M. J.**, Sch√ºtzenhofer, K., Ariza, A.‚úâ, Rack, J. G. M.‚úâ, Nielsen, M. L.‚úâ& Ahel, I.‚úâ Serine ADP-ribosylation in Drosophila provides insights into the evolution of reversible ADP-ribosylation signalling. Nat. Commun. 14, 3200 (2023).
18.	Goffinont, S., Coste, F., Prieu-Serandon, P., Mance, L., Gaudon, V., Garnier, N., Castaing, B. & **Suskiewicz, M. J.‚úâ** Structural insights into the regulation of the human E2‚àºSUMO conjugate through analysis of its stable mimetic. J. Biol. Chem. 299, (2023).
19.	Suskiewicz, M. J.‚úâ‚ú±, Munnur, D.‚ú±, Str√∏mland, √ò.‚ú±, Yang, J.-C., Easton, L. E., Chatrin, C., Zhu, K., Baretiƒá, D., Goffinont, S., Schuller, M., Wu, W.-F., Elkins, J. M., Ahel, D., Sanyal, S., Neuhaus, D. & Ahel, I.‚úâ Updated protein domain annotation of the PARP protein family sheds new light on biological function. Nucleic Acids Res. gkad514 (2023). doi:10.1093/nar/gkad514

The most recent publications might be missing - please visit <a href="https://scholar.google.ca/citations?user=Xsix4w8AAAAJ&hl=en">my Google Scholar profile</a>.

Summaries of selected publications
------
I'll try to update this part in the next weeks, adding one paper a week, together with a short summary (14.09.2023).

* **Structural insights into the regulation of the human E2‚àºSUMO conjugate through analysis of its stable mimetic**<br />
  Goffinont, S., Coste, F., Prieu-Serandon, P., Mance, L., Gaudon, V., Garnier, N., Castaing, B., Suskiewicz, M. J. ‚úâ<br />
  *Journal of Biological Chemistry*, 2023, 299(7)<br />
  <a href="https://www.jbc.org/article/S0021-9258(23)01898-7/fulltext">Link to the open-access article</a>

  During ubiquitylation and related reactions, ubiquitin or a related modifier is first loaded on a Cys residue in an E2 enzyme, producing an E2-modifier thioester. The modifier is discharged from there onto a Lys residue in a protein substrate, often with the help of an E3 ligase.

  SUMOylation is an essential ubiquitin-like modification. While ubiquitylation relies on numerous E2s, SUMOylation depends on a single one, UBC9, which is therefore the central protein of the pathway. UBC9's highly conserved, with sequence changing little from yeast to humans.

  Since the E2-modifier thioesters are unstable, our goal here was to produce a stable mimetic of human UBC9-SUMO. We used a strategy developed by the great Lima group for the yeast Ubc9, which involves introducing a Lys residue close in space to the active-site Cys93 of UBC9. We describe our attempt at this strategy in detail, and show that SUMO efficiently moves from Cys93 to a Lys placed in the position 129 through an Ala129Lys mutation, forming a stable molecule with SUMO attached 3 √Ö away from its native position in the UBC9-SUMO thioester.

  We crystallised this mimetic. In the absence of an E3 ligase, it adopts the so-called open conformation, which would likely correspond to an inactive state of the thioester. Indeed, all previous structures of UBC9-SUMO were with an E3 ligase, which stabilised the closed state. Interestingly, in the crystal, the mimetic forms chains via a noncovalent interaction between SUMO from one UBC9-SUMO molectule and UBC9 from the next one. We think such interactions can sometimes form in cells, sterically discouraging the active, closed state of UBC9-SUMO. Another interesting point concerns Cys138, a surface-exposed Cys in UBC9 with unclear function. In our open-conformation crystal structure, Cys138 is close to Cys52 of SUMO and they apparently became crosslinked by DTT. Could these Cys residues form a disulphide bridge under some conditions in cells?

  There're some other elements to the story, too. We've put emphasis on detailed description and discussion. We'd be happy if it's useful to the field.

  It's part of a larger line of research where we're trying different biochemical and chemical ways of stabilising SUMOylation complexes. It's the first publication from our SUMOwriteNread project. Our engineer St√©phane Goffinont played the first fiddle (thanks and congratulations!), with assistance from Franck Coste (crystal structure), Pierre Prieu-Serandon, and the rest of the team.

  We have <a href="http://cbm.cnrs-orleans.fr/en/actualite/structural-insights-into-the-sumoylation-reaction-2/">a short popular description of the article in English</a> on our Centre's website.

* **Updated protein domain annotation of the PARP protein family sheds new light on biological function**<br />
  Suskiewicz, M. J. ‚úâ‚ú±, Munnur, D.‚ú±, Str√∏mland, √ò.‚ú±, Yang, J. C., Easton, L. E., Chatrin, C., Zhu, K., Baretiƒá, D., Goffinont, S., Schuller, M., Wu, W.-F., Elkins, J. M., Ahel, A., Sanyal, S., Neuhaus, D., Ahel, I. ‚úâ<br />
  *Nucleic Acids Research*, 2023, 51(15):8217-8236<br />
  <a href="https://academic.oup.com/nar/article/51/15/8217/7199335">Link to the open-access article</a>

  In this side-project paper, we carefully analysed AlphaFold2 models of human members of the PARP protein family, made a comprehensive domain annotation, made new insights into structure & function, and experimentally validated some of them.

  We hope that the domain annotation will be a useful resource. We believe all structured domains within PARPs are now labelled. Some have not been reported before - for example, the KH domains, which are potential sequence-specific RNA- or ssDNA-binding domains, within PARP9, 10, & 14.

  I did most of the computational analysis and writing, while Deeksha & √òyvind from the Ivan Ahel lab (my former group) have done experiments demonstrating that PARP14 fragments can indeed bind to - and ADP-ribosylate - nucleic acids in vitro. David Neuhaus' team at MRC LMB Cambridge has contributed an interesting NMR experiment showing that while individual PARP1 domains have independent mobility in a DNA-free state, most of them cluster together upon DNA break binding - except for the BRCT domain, which remains flexible.
  
  In the  introduction, we tried to explain in a simple way the principles behind AlphaFold2 and introduce various recent easy-to-use tools for protein analysis. Hopefully this part might be interesting even for people working on some other protein families.

  The Institute of Chemistry of the CNRS has dedicated to this paper a nice <a href="https://www.inc.cnrs.fr/fr/cnrsinfo/lintelligence-artificielle-pour-predire-la-forme-des-proteines">news & views article in French</a>, and we have <a href="http://cbm.cnrs-orleans.fr/en/actualite/combining-computers-and-experiments-to-study-the-domain-composition-and-function-of-the-parp-protein-family-2/">a short note in English</a> on our Centre's website, too.
  
